Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer Acquisition of Caliper Clears Anti-Trust Review

NEW YORK (GenomeWeb News) – PerkinElmer today said that its planned acquisition of Caliper Life Sciences has cleared anti-trust reviews in the US and Germany.

The $600 million deal, which was signed early last month, still requires the approval of Caliper's stockholders, among other remaining conditions. The firms previously said that they expect the transaction to close in the fourth quarter of this year, but they didn't provide an update to that expectation today.

The deal will broaden PerkinElmer's reach in the life sciences research space, providing the firm with Caliper's portfolio of imaging, microfluidics, automation, and sample preparation platforms and technologies. It also will combine Caliper's imaging instrumentation for in vivo imaging applications with PerkinElmer's broad offering of imaging reagents and set up the combined firm with further growth opportunities in molecular diagnostics.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.